Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
用于治疗艾滋病毒的新型造血干细胞工程和移植方法
基本信息
- 批准号:10163906
- 负责人:
- 金额:$ 265.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-15 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS/HIV problemAllogenicAnimal ModelAntibody-drug conjugatesAntiviral AgentsAutologousBehavior TherapyBerlinBiomimeticsBiotechnologyBone MarrowCCR5 geneCell CompartmentationCell TransplantationCellsClinicalCombined Modality TherapyCommunicable DiseasesDNADNA RepairDataDefectDefense MechanismsDoseElementsEngineered GeneEngineeringEngraftmentEnvironmentFrequenciesGene CombinationsGenesGenetic EngineeringGoalsHIVHIV InfectionsHIV SeropositivityHIV resistanceHematologic NeoplasmsHematopoietic Stem Cell TransplantationHematopoietic stem cellsHumanImmuneImmune responseImmunityImmunoglobulin GImmunotherapyIndividualInfectionLeadLymphomaMacacaMalignant NeoplasmsMediatingMethodsModelingMutationNonhomologous DNA End JoiningOutcomePathway interactionsPatientsProductionPropertyProtocols documentationRegimenResearch PersonnelResistanceRosaniline DyesSafetySeriesSiteStem cell transplantT cell reconstitutionT cell responseT-Cell DevelopmentT-LymphocyteTechnologyTestingTherapeuticTherapeutic immunosuppressionToxic effectTranslatingTransplantationWorkantiretroviral therapyarmbasecancer therapycell regenerationchimeric antigen receptor T cellscombinatorialcomparative efficacyconditioningcryogelengineered T cellsengineered stem cellsgain of function mutationgene therapygenome editinggraft vs host diseasehumanized mouseimmune reconstitutionimmune resistanceimmunoreactionimprovedinhibitor/antagonistleukemiamouse modelnanobodiesneutralizing antibodynonhuman primatenovelnovel strategiespost-transplantpreservationprogramsrepairedside effectsimian human immunodeficiency virustargeted nucleases
项目摘要
Gene editing holds the promise of enhancing the precision and safety of anti-HIV gene therapies based on engineering hematopoietic stem and progenitor cells (HSPC), in order to recreate elements of the Berlin Patient cure. Targeted nuclease technology is already being used to exploit NHEJ-mediated repair of DNA breaks and thereby disrupt the CCR5 gene, which mimics one aspect of his cure. However, extending this treatment to noncancer patients, receiving engineered autologous HSPC, will likely need to include other approaches. To do this, we are exploiting the alternate pathway of DNA break repair based on homology-directed repair (HDR). This can be used to introduce gain-of-function mutations into cellular restriction factors, or to direct the controlled secretion of soluble anti-viral factors, including the broad entry inhibitor eCD4-Ig. Moreover, the site-specific insertion at eCD4-Ig at the CCR5 locus would combine HIV-resistance with systemic protection and thereby provide a combinatorial anti-HIV approach. In the current proposal we aim to continue to improve the safety and efficacy of gene editing in HSPC, and to apply the technology to provide both local and systemic HIV resistance. We will combine our established anti-HIV approaches with a new direction to engineer production of broadly neutralizing antibodies, and thereby provide a novel synthetic immune capability. Individual strategies and combination approaches will be evaluated in appropriate mouse models, to evaluate their impact on HIV infection and the latent reservoir.
基因编辑有望提高基于工程造血干细胞和祖细胞(HSPC)的抗HIV基因疗法的精确性和安全性,以重现柏林患者治愈的要素。靶向核酸酶技术已经被用于利用NHEJ介导的DNA断裂修复,从而破坏CCR 5基因,这模拟了他治愈的一个方面。然而,将这种治疗扩展到接受工程化自体HSPC的非癌症患者,可能需要包括其他方法。为了做到这一点,我们正在开发基于同源性定向修复(HDR)的DNA断裂修复的替代途径。这可用于将功能获得性突变引入细胞限制因子,或指导可溶性抗病毒因子(包括广泛进入抑制剂eCD 4-IG)的受控分泌。此外,在CCR 5基因座处的eCD 4-IG的位点特异性插入将联合收割机HIV抗性与系统性保护结合,从而提供组合抗HIV方法。在目前的提案中,我们的目标是继续提高基因编辑在HSPC中的安全性和有效性,并应用该技术提供局部和全身的HIV抗性。我们将联合收割机将我们已建立的抗艾滋病毒方法与设计广泛中和抗体生产的新方向相结合,从而提供一种新型的合成免疫能力。将在适当的小鼠模型中评价单个策略和组合方法,以评价其对HIV感染和潜伏储库的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paula M Cannon其他文献
Erratum to: HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment
- DOI:
10.1186/1742-4690-8-85 - 发表时间:
2011-10-25 - 期刊:
- 影响因子:3.900
- 作者:
Heiko Hauser;Lisa A Lopez;Su Jung Yang;Jill E Oldenburg;Colin M Exline;John C Guatelli;Paula M Cannon - 通讯作者:
Paula M Cannon
Paula M Cannon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paula M Cannon', 18)}}的其他基金
Nuclear receptor regulation of epigenetic mechanisms regulating HIV CNS latency
表观遗传机制的核受体调节调节HIV中枢神经系统潜伏期
- 批准号:
10747002 - 财政年份:2023
- 资助金额:
$ 265.82万 - 项目类别:
Gene edited B cells to co-express CNS-targeted antibodies
基因编辑 B 细胞共表达 CNS 靶向抗体
- 批准号:
10475527 - 财政年份:2022
- 资助金额:
$ 265.82万 - 项目类别:
Gene edited B cells to co-express CNS-targeted antibodies
基因编辑 B 细胞共表达 CNS 靶向抗体
- 批准号:
10589115 - 财政年份:2022
- 资助金额:
$ 265.82万 - 项目类别:
Combination gene editing for local and systemic HIV resistance
局部和全身艾滋病毒耐药性的组合基因编辑
- 批准号:
10601081 - 财政年份:2020
- 资助金额:
$ 265.82万 - 项目类别:
Combination gene editing for local and systemic HIV resistance
局部和全身艾滋病毒耐药性的组合基因编辑
- 批准号:
10163911 - 财政年份:2020
- 资助金额:
$ 265.82万 - 项目类别:
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
用于治疗艾滋病毒的新型造血干细胞工程和移植方法
- 批准号:
9891825 - 财政年份:2020
- 资助金额:
$ 265.82万 - 项目类别:
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure
用于治疗艾滋病毒的新型造血干细胞工程和移植方法
- 批准号:
10601061 - 财政年份:2020
- 资助金额:
$ 265.82万 - 项目类别:
Combination gene editing for local and systemic HIV resistance
局部和全身艾滋病毒耐药性的组合基因编辑
- 批准号:
10409805 - 财政年份:2020
- 资助金额:
$ 265.82万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 265.82万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 265.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 265.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 265.82万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 265.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 265.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 265.82万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 265.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 265.82万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 265.82万 - 项目类别:
Grant-in-Aid for Scientific Research (B)